Clinical Trial: A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia
Brief Summary: To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80.
Detailed Summary:
Sponsor: Glaxo Wellcome
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: NIH AIDS Clinical Trials Information Service
Dates:
Date Received: November 2, 1999
Date Started:
Date Completion:
Last Updated: June 23, 2005
Last Verified: April 2003